Hematology-2013
OMICS Group Conferences
Accelerating Scientific Discovery
International Conference on
Hematology & Blood Disorders
September 23-25, 2013 Raleigh, USA

Te-MPN- thrombotic events in Myeloproliferative neoplasms: JAK2V617F mutation as a predictive marker

Adel GOURI
IBN ZOHR Public Hospital, Algeria

Abstract

Thrombotic complications are a common cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). The pathogenesis of thrombosis in MPN is multifactorial and complex. Recently, several studies suggest that JAK2V617F mutation plays an important role in the pathogenesis of thrombosis. This mutation is present in almost all the PV patients and in 50-60% of ET patients. This relationship suggests a direct influence of the JAK2 mutation on the hemostatic system. Current data indicate that JAK2V617F mutation positivity seem to be predictive biomarker of cardiovascular and thrombotic complications in patients with MPN. However, future research should focus on the pathophysiology of thrombosis in myeloproliferative disorders, particularly in terms of the relationship between dysregulated Janus kinase 2 and thrombotic risks.